Freeflow is a venture capital firm focused on investing in and supporting deep tech, science-driven companies primarily emerging from the founder communities of Caltech, JPL, and Berkeley. The firm specializes in identifying high-growth opportunities in human and planetary health sectors, leveraging its expertise in healthcare, life sciences, software, big data, and machine learning. Freeflow prides itself on being a strategic partner to founders, providing guidance in fundraising, marketing, recruitment, and strategy, and connecting them with a vast network of experts, business partners, and investors.

Freeflow

Freeflow is a venture capital firm focused on advancing science to benefit humankind and our planet. Our thesis is that science will unlock the transformations at scale that we need to survive and thrive. Our community of portfolio companies comes from Caltech and JPL where groundbreaking science research and deep tech innovation abound. Visit https://www.freeflow.io/ to learn more.

The GPs are David Fleck and Kevin Barrett, two longtime technology, life sciences and healthcare industry veterans who bring more than 50 combined years of technology and healthcare industry experience.

Fred Wilson (Union Square Ventures), Chris Farmer (SignalFire) and Chris Douvos (Ahoy) represent the board of advisors and are also investors.

To date our syndicate partners include: 8VC, Sequoia, Coatue, Catalio Capital Management, Nexus Venture Partners, OrbiMed, Embark Ventures, Dolby Family Ventures, Hillhouse Capital, Cultivation Capital, Techstars, Synovia Capital, Heritage, Wilson Hill, and Caltech.

Freeflow Ventures

There is growing consensus that human impact on the environment has placed our planet into a new geological period of time called the Anthropocene. 

In this blog post from Operating Partner Stephen Roy, we cover the forces guiding our investments in planetary health while featuring portfolio companies Hydrosat and Captura.

https://lnkd.in/gat4m-gZ

We're hosting a discussion that will focus on portfolio company StrokeDx on Wednesday, June 21st at 8am Pacific / 11am Eastern. You can register via the following link on Zoom. 

StrokeDx is a human health startup developing next-generation technology that will transform how strokes are diagnosed and treated. Based on technology developed at Caltech, the innovative, portable StrokeDx neuroimaging device will dramatically reduce the time to diagnose and treat strokes. Most recently, StrokeDx has been named to the MedTech Innovator (MTI) 2023 Cohort - MTI is the world's largest and most competitive medical device accelerator.  

The discussion will kick off with a presentation and introductory remarks from StrokeDx Co-founders Shane Shahrestani and Alexander Ballatori. 

Please join us!

https://lnkd.in/eb964J9s

We’re excited to invite you to our next Founder Session featuring Switch Therapeutics on Thursday May 25th at 8am Pacific / 11am Eastern. Register here to attend the live event. 

https://lnkd.in/gemxgpcR

Switch is pioneering a new way to use RNA science to treat diseases based on research conducted in part at Caltech. In March, the company announced its launch following a $52M Series A financing round. 

Learn more below.  We hope you can join us.

Freeflow Founder Session: Switch Therapeutics

Invitation: 

Freeflow Ventures is hosting a discussion that will focus on portfolio company Switch Therapeutics on Thursday, May 25th at 8am Pacific / 11am Eastern.  

Switch Therapeutics was founded in 2020 to develop therapeutic applications from RNAi research conducted at Caltech, Harvard Medical School and City of Hope. In March of this year, the company officially launched following its $52 million Series A financing round.

“This is a transformational era for RNA medicines and we’re excited to apply our scientific discoveries in ways that could lead to new therapeutic breakthroughs, with the potential to treat some of the most devastating diseases,” said Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics. “Our approach uses novel CASi molecules that are uniquely able to self-deliver efficiently, have high potency and long duration of effect. Additionally, we can design CASi molecules to activate only in select cells, allowing for expansion into targets that may require precision RNAi approaches.”

Learn more about the company at https://switchthera.com/

The discussion will kick off with a presentation and introductory remarks from Dee Datta, PhD​ Co-Founder & CEO at Switch Therapeutics. Dee received her PhD from Caltech and MBA from Stanford University Graduate School of Business. Before Switch, Dee was the Chief Business Officer at XOMA. After her opening presentation, it will be followed by Q&A with Freeflow and concluded with questions from the audience. 

Please join us!

List of speakers: 
-Dee Datta, PhD​, Co-Founder & CEO at Switch Therapeutics
-David Fleck, Founder and Managing Partner, Freeflow Ventures
-Kevin Barrett, Managing Partner, Freeflow Ventures 

When: Thursday, May 25th at 8am Pacific / 11am Eastern

Hello!

If you’re in the greater Los Angeles area or Pasadena, please join us at the Rath Al Fresco on the Caltech campus from 5:30 - 7:30 pm on Wednesday May 3rd for an entrepreneurs networking event. 

This is a great opportunity for entrepreneurs, innovators, and startup enthusiasts to network and exchange ideas. There will be beverages and light refreshments served, and the event is free to attend. Feel free to share this message with anyone in your network you think might be interested.
 
More information is available on the below registration page. 

https://lnkd.in/gqHat5Hn


Metric
Company Name	Freeflow
Symbol
MSH ID	IO:FREEFLOW
Market	PRIVATE
Sector	Financial Services & Finance
Industry	Venture Capital & Private Equity
Country	US
Stage
Employee Count	6
Website	freeflow.io
LinkedIn	freeflow-ventures
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

IO:FREEFLOW

Freeflow

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue